by Barry | Sep 29, 2022 | Press Releases
CORALVILLE, IA / September 29, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic...
by Barry | Feb 22, 2022 | Press Releases
Fireside chat with newly appointed CEO, Thijs Spoor, today, February 22 at 1:30 PM ETCORALVILLE, IA / February 22, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a precision oncology company developing alpha-particle...
by Barry | Feb 22, 2022 | Press Releases
Established leader with nearly 30 years of combined executive, broad management and capital markets expertise across healthcare and medical device industriesCORALVILLE, IA / February 22, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the...
by Barry | Jan 20, 2022 | Press Releases
– Live video webcast presentation on Tuesday, January 25th at 11:00 AM ETCORALVILLE, IA / January 20, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision...
by Barry | Jan 5, 2022 | Press Releases
CORALVILLE, IA / January 5, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging...
by Barry | Dec 21, 2021 | Press Releases
Optimized 203Pb/212Pb image-guided alpha-particle radionuclide therapy for SST2R expressing tumors Preclinical data of VMT- alpha-NET demonstrated to significantly improve cell binding, tumor accumulation/retention and renal clearance of an SSTN analog VMT- alpha-NET...
Recent Comments